|
New Approaches to LDL Reduction
|
|
|
Inhibition of Cholesterol Absorption and Production With Ezetimibe/Simvastatin
|
|
|
Cholesterol Balance in Mice (µmol/day.100 g body wt)
|
|
|
Ezetimibe strongly increases TICE
|
|
|
Cholesterol Fluxes in Humans(mg/day.70 kg body wt)
|
|
|
Next Steps
|
|
|
|
ENHANCE
|
|
|
ENHANCE - Logical Next Step After ASAP -
|
|
|
ENHANCE Study Population
|
|
|
ENHANCE Study Design
|
|
|
Baseline Characteristics
|
|
|
LDL-Cholesterol
|
|
|
ENHANCEhsCRP
|
|
|
|
Possible Explanations for the Absence of an Incremental Reduction in cIMT
|
|
|
The Trial Design and Population
|
|
|
Critical Factors for Successful cIMT Trial
|
|
|
Critical Factors for Successful cIMT Trial
|
|
|
ASAP and ENHANCE Baseline cIMT in LIPID (Pediatric)
|
|
|
|
|
Conclusion from ENHANCE
|
|
Share this page with your colleagues and friends: